Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling

This study found that JAK inhibitors used to treat alopecia areata have varied safety profiles, with different adverse events associated with each drug; tofacitinib and ruxolitinib had earlier onset of events, while baricitinib and ritlecitinib showed distinct delayed patterns.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

In this study, the researchers using Shh-GFP^+/- mice found that cyclophosphamide-induced alopecia involves the JAK/STAT1 pathway, where STAT1 binds the Shh gene promoter, decreasing Shh-expressing cells in hair follicles. Treatment with JAK inhibitors helped rescue hair loss, implicating the JAK/STAT1 pathway in this process.

Low-dose oral minoxidil can effectively promote hair growth but requires careful monitoring for safety.

In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This opinion piece discusses strategies for managing cancer-related alopecia, emphasizing personalized approaches including scalp cooling and topical minoxidil, but it reports no new clinical results.

Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.

In this study, researchers examined trichoscopic features in a cohort of Black patients with alopecia areata, identifying both common and novel characteristics, but found no statistical link between these features and the severity of alopecia.

This retrospective cohort study found no significant association between Janus kinase inhibitors and increased malignancy risk in alopecia areata patients, but traditional immunosuppressants were linked to higher risks of internal and hematologic malignancies.

This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.

In this real-world study, JAK inhibitors like abrocitinib and tofacitinib led to substantial hair regrowth in 61% of alopecia areata patients over a median of 16 months, with 75% of non-responders achieving regrowth after switching medications; however, two serious adverse events were noted.

This study investigated using baricitinib-loaded mesenchymal stem cell exosomes injected locally in an alopecia areata mouse model and found that this method improved hair regrowth better than baricitinib or exosomes alone, potentially offering a new therapeutic approach for treating alopecia areata.

In this study, seven patients with refractory alopecia areata treated with concentrated growth factor and microneedling-assisted betamethasone experienced significant hair regrowth, with one achieving over 50% regrowth and six showing complete recovery, without adverse effects.

This article reviews the pathophysiology of chemotherapy-induced alopecia and reports that scalp cooling can reduce hair loss by 50% in patients with early breast cancer receiving chemotherapy, without compromising survival or increasing scalp metastasis risk.

This study found that oral minoxidil improved hair density in women experiencing late alopecia due to chemotherapy and/or endocrine therapy, with 74% showing clinical improvement and statistically significant increases in hair shaft density reported in those assessed with trichoscopy.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

This study found that while infectious events may occur in alopecia areata patients treated with JAK inhibitors, these infections are usually manageable and rarely lead to permanent treatment discontinuation.

This study found that rhIL-15 promotes human hair follicle growth and regrowth in experimental settings and may have therapeutic potential for alopecia areata by restoring immune privilege guardianship.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This review highlights recent insights into how IL-15 influences T cell responses and contributes to immunopathogenesis in various diseases, suggesting its crucial role in TCR-independent activation and potential in optimizing therapeutic strategies.

This review highlights the importance of apoptosis in the hair cycle, particularly its role in hair follicle regression and loss, suggesting that understanding its mechanisms can aid in developing treatments to reduce hair loss and promote hair growth.

This study highlights that while hair follicle cycling is primarily influenced by growth factors like IGF-1 and Wnt signals, the role of cytokines in normal human hair growth and cycling is less understood.

This review discusses the association between emotional stress-related neuropeptides and the pathogenesis of alopecia areata, reporting no new experimental findings.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

This review discusses the association between oxidative stress and alopecia areata while proposing antioxidants as a potential supplementary therapy, but it reports no new clinical results.

This study reviewed 39 studies with 3204 patients to identify characteristic trichoscopic findings in alopecia areata, highlighting yellow and black dots, broken, short vellus, and tapering hairs as key indicators. It found no single diagnostic trichoscopic finding but observed trichoscopy's utility in monitoring treatment response.

This study observed that patients with alopecia areata had significantly higher serum levels of IL-15 and TNF-α compared to controls, with TNF-α levels particularly elevated in individuals with alopecia totalis, though these biomarkers were not influenced by disease duration or activity.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This study suggests that IL-17 may play a more significant role than IFN-γ in the pathogenesis of chronic alopecia areata, with increasing severity linked to Th17 lymphocytes and cytotoxic T lymphocyte infiltration.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review discusses the epidemiology, clinical characteristics, pathogenesis, and genetic factors of alopecia areata, while stressing the need for targeted and effective treatments, but reports no new clinical results.

In this animal study, topical pentoxifylline was associated with improved hair regrowth in cyclophosphamide-induced hair loss in male Swiss albino rats.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This paper reviews various causes of alopecia in cancer patients and highlights the importance of understanding these mechanisms for effective management, but reports no new findings.

This study reports that persistent chemotherapy-induced alopecia in breast cancer patients frequently resembles androgenetic alopecia, and treatment with minoxidil, alone or with antiandrogens, improved hair density in many cases.

This study suggests that pretreatment with a PPAR-γ modulator may prevent damage to hair follicle stem cells caused by a chemotherapy metabolite, potentially offering a strategy to mitigate permanent chemotherapy-induced alopecia.

In this study, selective inhibition of JAK3 signaling effectively prevented and reversed alopecia areata in a mouse model, while JAK2 inhibitors did not restore hair growth.

This study found that ruxolitinib modulated inflammatory changes and stimulated growth factor signals by blocking the JAK-STAT pathway in an in vitro model of alopecia areata.

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

This study found that the CDK4/6 inhibitor palbociclib may protect human hair follicles from the damaging effects of taxane chemotherapy by inducing G1 arrest in stem/progenitor cells.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

In this study, researchers found that alkylating chemotherapy causes hair follicle stem cells to lose their regenerative ability by initially triggering proliferation followed by apoptosis, leading to permanent regeneration loss.

This study identified 19 genes targeted by 29 potential drugs for topical treatment of chemotherapy-induced alopecia, suggesting avenues for drug repositioning in pharmaceutical research.

This study found that persistent chemotherapy-induced alopecia is often more severe and diffuse than alopecia from endocrine therapy, with both conditions negatively impacting patients' emotional wellbeing, and moderate to significant improvement was observed with dermatologic therapy.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This article reviews therapy-related hair disorders in oncology patients, detailing underlying mechanisms and potential management strategies, but reports no new clinical findings.

This review discusses the roles of interferon-γ and PPAR-γ-mediated signalling in scarring alopecia, suggesting these pathways as potential therapeutic targets, but it reports no new empirical results.

This study found that alopecia areata patients had a slightly decreased overall cancer risk, with significantly lower risks for some cancers but higher risks for lymphoma, breast, kidney, and urinary bladder cancers.

This review presents various trichoscopic findings for diagnosing alopecia areata but reports no new clinical results, emphasizing that no single marker is pathognomonic and multiple features should be considered together.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This review discusses the role of immune privilege collapse in the pathogenesis of alopecia areata, emphasizing the potential for therapeutic manipulation of hair bulb immune privilege to offer new treatment options, and reports no new results.

PPAR-γ agonists like pioglitazone may help manage lichen planopilaris but don't fully reverse scarring.

In this study, topical tofacitinib significantly increased hair regrowth in mice compared to minoxidil or vehicle, potentially due to elevated VEGF levels and reduced inflammation.

This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.

This study found that in a neonatal rat model, skin wounding protected against chemotherapy-induced alopecia through IL-1β signaling, making hair follicles more resistant to damage when wounding exposure was timed correctly.

This study observed various patterns of permanent alopecia in breast cancer patients treated with taxanes and adjuvant hormonal chemotherapy, hypothesizing disruptions in hair follicle cycles due to chemoinflammatory and hormonal factors.

This proposal reviews current knowledge and suggests actions for managing chemotherapy‐induced alopecia but reports no new clinical results, highlighting the need for evidence‐based guidelines.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This study found that activating Nrf2 in human hair follicles significantly reduced oxidative stress, lipid peroxidation, and protected against hair growth inhibition, suggesting a protective role for Nrf2 against redox insult in this context.

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

This review discusses alopecia areata, highlighting its autoimmune aspects, environmental triggers, and current treatment options, but reports no new clinical results; recent studies suggest JAK pathway intervention may offer therapeutic potential.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

This article discusses the role of human hair follicles in neuroendocrinology and suggests potential new therapeutic targets by examining how neuromediators influence hair growth, pigmentation, and stem cell biology in organ cultures.

This study found an association between hydroxyl radical-modified SOD and alopecia areata, suggesting these modifications may lead to antibody induction in the condition.

This study found that chemotherapy in female breast cancer patients caused significant early hair loss, which began to recover three months after completion, whereas tamoxifen did not affect hair growth.

This study identified a specific SNP in the CACNB4 gene associated with a higher risk of chemotherapy-induced alopecia in breast cancer patients, which may help develop interventions to improve their quality of life.

This article shares the researchers' challenging journey in exploring the pathobiology of alopecia areata and reports no definitive clinical advances.

The researchers reported that reactive oxygen species regulate the stress-induced SP-Mast cell pathway, which might support using antioxidants to treat stress-related hair loss.

This review discusses the pathobiology of chemotherapy-induced alopecia and highlights challenges in managing it, reporting no new clinical results and emphasizing the need for well-designed preclinical models to develop effective treatments.

This article reviews trichoscopic signs of chemotherapy-induced alopecia, including exclamation marks, but reports no new clinical results.

This study found that 'black dots' seen under trichoscopy are not specific to alopecia areata and may occur in various other hair and scalp conditions.

This review discusses current knowledge and management strategies for chemotherapy-induced alopecia, highlighting the need for better research prioritization and providing patient support materials, but reports no new clinical results.

This study suggests that the neuropeptide CGRP may protect against, but not restore, IFNγ-induced collapse of hair follicle immune privilege in alopecia areata.

IL-6 contributes to hair loss by shortening the growth phase and causing hair follicles to regress.

In this study, cisplatin was found to induce cell death in human hair follicle cells through hydroxyl radical generation and Bcl-2 down-regulation, suggesting potential strategies for preventing chemotherapy-induced alopecia.

This study suggests that TGF-β 2 plays a critical role in hair follicle morphogenesis and may enhance the effectiveness of future cell therapies for hair regrowth using expanded dermal papilla cells.

This review covers various strategies to manage chemotherapy-induced alopecia, highlighting that agents like AS101 and minoxidil can reduce its severity but not prevent it, with no new clinical results reported.

This study found that dermoscopic indicators like black dots and tapering hairs are valuable markers for diagnosing and assessing the severity and activity of alopecia areata in Asian patients.

This study suggests that human hair follicles may actively suppress natural killer cells, which contrasts with the observed defects in NK cell regulation in alopecia areata.

In this study, researchers found that substance P triggered premature catagen development and immune changes in human scalp hair follicles, providing a possible biological link between stress and hair loss conditions like telogen effluvium and alopecia areata.

This study found that organ-cultured human scalp hair follicles can mimic chemotherapy-induced damage in vivo and serve as a model to explore molecular targets and protective agents for hair follicle preservation.

This study found that doxorubicin disrupts hair-follicle-associated blood vessels, which may contribute to hair follicle dystrophy and alopecia in mice, but hair-follicle stem cells remained unaffected.

This study defines classification criteria for hair follicle dystrophy using a mouse model of chemotherapy-induced alopecia, providing tools for standardized hair damage assessment.

This study found that human scalp hair follicles can respond to corticotropin releasing hormone stimulation similarly to the classical HPA axis, including up-regulating cortisol production and activating neuroendocrine feedback loops.

This study found that premature hair loss due to stress does not occur in NK-1 receptor knockout or mast cell deficient mice, suggesting a key role for neurokinin substance P and mast cell interaction in stress-related hair follicle changes.

This study suggests that stress negatively affects hair growth by inducing inflammation and early hair cycle transitions in mice, which might inform strategies for managing stress-related hair loss in humans.

This study found that psychoemotional stress disrupts hair growth in mice by terminating anagen and suggests a potential pathway for pharmacological management of stress-related hair loss in humans.

This case report documents a cancer survivor who experienced cyclic alopecia areata following chemotherapy, suggesting potential autoimmune changes related to the treatment.

This study demonstrated that stress inhibited hair growth in mice, likely through substance P-dependent activation of immune cells, highlighting a brain-hair follicle connection.

This study found that cyclophosphamide-induced hair follicle damage in C3H mice could be remodelled into intact anagen hair follicles with topical cyclosporin A, especially in anagen IV stage follicles.

In this study, different types of catagen in the C57BL/6 mouse model exhibited varying effects on hair follicle melanocytes and melanin distribution, with spontaneous and dexamethasone-induced catagen showing pigment incontinence, while cyclophosphamide-induced catagen retained dendritic melanocytes but increased ectopic melanin.

This study found that cyclophosphamide induced significant keratinocyte apoptosis in anagen hair follicles of mice, while topical calcitriol-analogs reduced this apoptosis, suggesting a protective effect against chemotherapy-induced alopecia.

In this study, AS101 combined with chemotherapy significantly reduced the severity of chemotherapy-induced alopecia in non-small-cell-lung-cancer patients and may involve immune mechanisms related to IL-1 and PGE2.

The document describes how to tell different types of non-scarring hair loss apart by looking at hair and scalp tissue under a microscope.